Pretzel Therapeutics Advances PX578 into Phase 2 for POLG-Mediated Mitochondrial Disease
Pretzel Therapeutics Receives FDA Clearance to Advance PX578 Into Phase 2 Study for POLG-Mediated Mitochondrial Disease Pretzel Therapeutics, Inc., a clinical-stage biotechnology company focused on developing a new generation of…
Ivonescimab Plus Chemotherapy Phase III HARMONi Results Published in The Lancet Oncology
Ivonescimab Plus Chemotherapy Phase III HARMONi Results Published in The Lancet Oncology Summit Therapeutics Inc. has announced the publication of primary analysis results from its global Phase III HARMONi clinical…
Copia Scientific Partners with HSE•AG to Expand Automated Nucleic Acid Quantification in North America
Copia Scientific and HSE•AG Partner to Expand On-Deck Nucleic Acid Quantification for Laboratory Automation Copia Scientific, a provider of laboratory automation, equipment, integration and technical service solutions, has announced a…
GeneDx Study Supports Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
GeneDx Study Shows Hospital-Wide Rapid Genome Sequencing Can Improve Pediatric Diagnosis, Outcomes and Health System Efficiency GeneDx (Nasdaq: WGS), a company focused on rare disease diagnosis and the use of…
Spruce Biosciences Reports Positive FDA Meetings and Advances TA-ERT BLA Submission for Q4 2026
Spruce Biosciences Advances Toward 2026 BLA Submission for Tralesinidase Alfa in Sanfilippo Syndrome Type B Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for…
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer to Advance Clinical Development Pipeline AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics through…
TwinStrand Wins $245.2M Patent Infringement Judgment Against Guardant Health
TwinStrand Biosciences Secures More Than $245 Million Judgment in Patent Infringement Case Against Guardant Health TwinStrand Biosciences, Inc., the developer of Duplex Sequencing® technology, announced that the U.S. District Court…
European Commission Expands Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status
European Commission Broadens Trodelvy’s First-Line Use in Metastatic Triple-Negative Breast Cancer Regardless of PD-L1 Status Gilead Sciences, Inc.announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab…
Precision BioSciences Begins Dosing in Phase 1/2 FUNCTION-DMD Trial
Precision BioSciences Doses First Patient in Phase 1/2 FUNCTION-DMD Trial of PBGENE-DMD for Duchenne Muscular Dystrophy Precision BioSciences, Inc., a clinical-stage gene editing company developing in vivo therapies for diseases…
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Drive Growth of Innovative Portfolio
Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Accelerate Global Oncology and Specialty Medicine Growth Daiichi Sankyo has announced the appointment of Ken Keller to the newly created…
ORZEYFUL (oveporexton) Receives Japanese Approval as the First and Only Treatment Targeting the Underlying Cause of Narcolepsy Type 1
ORZEYFUL (oveporexton) Gains Japanese Approval as the First and Only Medicine Addressing the Underlying Cause of Narcolepsy Type 1 Takeda has announced that Japan’s Ministry of Health, Labour and Welfare…
AbbVie to Present New Lung Cancer Pipeline Data at WCLC 2026
AbbVie Highlights New Lung Cancer Research Data Across NSCLC and SCLC Programs at WCLC 2026 AbbVie is showcasing a broad collection of new research findings across its lung cancer development…